Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

US Patent 12173058 · Granted Dec 24, 2024

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta2021
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta2021
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta2021
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta2021
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta2021
FGFR inhibitor for use in the treatment of hypophosphatemic disorders2018
Compositions and methods for use for antibodies against sclerostin2011